Literature DB >> 11490535

HLA-B27 transgenic rats model.

M Breban1.   

Abstract

To investigate the role of HLA-B27 in the pathogenesis of spondylarthropathies, rats transgenic for HLA-B27 and human beta 2-microglobulin were produced. Several lines of B27 transgenic rats spontaneously develop a multisystem inflammatory disorder reminiscent of human spondylarthropathies, with gut, joint, skin and male genital lesions. The role of HLA-B27 in this model was studied and it was found that a high expression level of the transgene in cells of hematopoietic origin was critical to induce inflammatory manifestations. Furthermore, a combined implication of CD4+ T cells and antigen presenting cells in this model is suspected, based on passive transfer studies, although a specific influence of HLA-B27 upon T cell education in the thymus is unlikely to be important. Beside the immune system, bacterial flora exerts an important influence in this model, as a triggering agent of gut and joint inflammation. Finally, endogenous rat genetic factors are suspected to be involved in this model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11490535

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  3 in total

1.  The chronic colitis developed by HLA-B27 transgenic rats is associated with altered in vivo mucin synthesis.

Authors:  M Faure; D Moënnoz; C Mettraux; F Montigon; E J Schiffrin; C Obled; D Breuillé; J Boza
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

2.  A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat.

Authors:  James C Keith; Irma M Sainz; Irma Isordia-Salas; Robin A Pixley; Yelena Leathurby; Leo M Albert; Robert W Colman
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

3.  Non-invasive imaging demonstrates clinical features of ankylosing spondylitis in a rat adjuvant model: a case study.

Authors:  N Accart; J Dawson; F Kolbinger; I Kramer; N Beckmann
Journal:  Eur J Histochem       Date:  2016-11-02       Impact factor: 3.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.